 · VcallConferences · Annual Reports Service |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other May 13 Calls Today's Calls |
| Call Details | |||
| NexMed First Quarter 2008 Results Conference Call Tue, May 13, 2008, 10:00 am Eastern
| |||
| About NexMed, Inc. (NasdaqCM:NEXM) | |||
| NexMed, Inc., a pharmaceutical and medical technology company, engages in designing, developing, manufacturing, and marketing pharmaceutical products in the United States and Hong Kong. The company is leveraging its proprietary drug technology, NexACT, to develop a pipeline of pharmaceutical products to address significant unmet medical needs. It develops transdermal treatments based on the NexACT drug delivery technology, which might enable an active drug to be better absorbed through the skin. The company also develops treatments for sexual dysfunction and nail fungus based on its proprietary NexACT drug delivery technology. Its products under development include Alprox-TD, which is an alprostadil-based cream treatment intended for patients with erectile dysfunction; and Femprox, an alprostadil-based cream product intended for the treatment of female sexual arousal disorder. The company has a licensing agreement with Novartis International Pharmaceutical, Ltd. for the development, manufacture, and commercialization of NM100060, a nail lacquer treatment for onychomycosis. NexMed was founded in 1987 and is based in East Windsor, New Jersey. | |||
More Info: | |||
